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To date, 92,111,432 of coronavirus disease 
2019 (COVID-19), cases were confirmed worldwide 
and the number of asymptomatic patients remains 
largely unknown. There are emerging retrospec-
tive data implying that the COVID-19 infection has 
long-term complications, although there is still 
a paucity of large, prospective trials to investigate 
the true prevalence of these complications. Besides 
lung inflammation, myocardial injury is a typical 
COVID-19-related phenomenon, present in 20–30% 
of patients and contributing to 40% of deaths [1]. 
However, myocardial injury in the course of 
COVID-19 may be even more prevalent [2].
An autopsy study including 39 patients who 
had died due to COVID-19 showed features of 
myocardial abnormalities in patients, in whom 
the cardiac complications had not previously been 
diagnosed [3]. Histopathologic evaluation of the 
myocardium did not fulfil the criteria of acute 
myocarditis, but in 62% patients (24/39) the pres-
ence of severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2) was confirmed within 
the myocardium. Among them, 67% of patients 
(16/24) demonstrated evidence of myocardial vi-
rus replication, as defined  by a virus load above 
1,000 virus copies per μg RNA. In addition, the 
cytokine response panel consisting of 6 proinflam-
matory genes was increased in those 16 patients, 
compared with patients without SARS-CoV-2 in 
the heart, but this had not (yet) been associated 
with an influx of inflammatory cells. As assessed 
using in situ hybridization, interstitial cells and 
infiltrating macrophages, but not cardiomyocytes 
were the most probable virus localization within 
the myocardium [3].
The silent but progressive myocardial injury 
in the course of COVID-19 might contribute to the 
development of heart failure and other cardiovas-
cular complications following virtual recovery. This 
hypothesis is confirmed by the results of another 
study, where the authors performed cardiac mag-
netic resonance in 100 COVID-19 convalescents 
at 2 to 3 months following the acute phase of the 
disease [4]. Persistent cardiac involvement was 
observed in 78 (78%) patients and ongoing myo-
cardial inflammation in 60 (60%) patients, which 
was independent of the severity and overall course 
of the acute disease and the time from the original 
diagnosis. Moreover, increased troponin concen-
tration was demonstrated in 76 (76%) of patients 
without any clinically overt signs and symptoms 
of myocardial dysfunction.
In another study including 139 healthcare 




2021, Vol. 28, No. 2, 353–354
DOI: 10.5603/CJ.a2021.0028 
Copyright © 2021 Via Medica
ISSN 1897–5593 
eISSN 1898–018X
Letter tO the eDItOr
tion, cardiac magnetic resonance features of myo-
carditis were observed in 37% of the participants 
at a median of 10 weeks after infection [5]. Impor-
tantly, only half of the participants had symptoms 
of COVID-19, demonstrating that cardiac sequelae 
might be associated with an altered or delayed 
immune response, and that even asymptomatic 
patients and/or patients not aware of the infection 
may suffer from serious cardiovascular complica-
tion in the longer perspective.
The long-term health consequences of 
COVID-19 were also evaluated in 1733 patients 
with COVID-19 in Wuhan, China [6]. Six months 
following hospital discharge, the main persist-
ing symptoms were fatigue or muscle weakness 
(1038/1655, 63%), sleep difficulties (437/1655, 
26%) and anxiety or depression (367/1733, 23%). 
In addition, 76% of patients (1265/1655) declared 
at least one persisting symptom. In addition, 13% 
(107/822) participants without acute kidney injury 
and with normal estimated glomerular filtration rate 
(eGFR more than 90 mL/min/1.73 m2) in the acute 
phase had eGFR less than 90 mL/min/1.73 m2 at 
follow-up, implying the COVID-19-induced kidney 
injury [6]. Although cardiovascular imaging was not 
a part of this study, it is likely that at least a part of 
patients who reported the fatigue and muscle weak-
ness might have developed cardiac dysfunction.
Altogether, emerging results from the hitherto 
studies indicate that SARS-CoV-2 infection may 
be associated with the long-term extrapulmonary 
organ manifestations, with cardiac involvement 
being one of the most prevalent. The long-term 
impact of COVID-19-associated cardiac dysfunction 
remains unknown. Hence, it is relevant to evaluate 
the presence of the potential myocardial damage in 
patients with a history of SARS-CoV-2 infection, 
even if the course was asymptomatic. Moreover, it 
is crucial to focus on the group of patients who were 
not aware of the infection, as the post-COVID-19 
heart syndrome might be the first indicator of past 
infection [7]. In the societal perspective, there is 
a risk that SARS-CoV-2 might further increase the 
cardiovascular morbidity and mortality [8]. Further 
long-term studies are required to determine the 
incidence and clinical course of myocardial dam-
age caused by COVID-19 in order to implement 
a routine cardiac imaging screening that allows for 
the treatment of post-COVID-19 heart syndrome.
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